Sarepta Additional Paid In Capital from 2010 to 2024
| SRPT Stock | USD 133.34 4.60 3.33% |
Additional Paid In Capital | First Reported 2011-06-30 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 278.9 M |
Check Sarepta Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sarepta Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 61.8 M, Interest Expense of 23.1 M or Selling General Administrative of 475.9 M, as well as many indicators such as Price To Sales Ratio of 6.81, Dividend Yield of 0.0 or PTB Ratio of 6.7. Sarepta financial statements analysis is a perfect complement when working with Sarepta Therapeutics Valuation or Volatility modules.
Sarepta | Additional Paid In Capital |
Latest Sarepta Therapeutics' Additional Paid In Capital Growth Pattern
Below is the plot of the Additional Paid In Capital of Sarepta Therapeutics over the last few years. Additional Paid In Capital (or APIC) is an accounting term found on Sarepta Therapeutics Balance Sheet under Shareholders Equity. It is the value of the shares of the company above what they were issued it. The basic calculation is as follow: (Issue Price - Par Value) x Sarepta Therapeutics Shares Outstanding. Additional Paid In Capital is not affected by secondary trading of Sarepta Therapeutics shares and does not have any impact on the value of APIC. It is the excess amount paid by investors over the par value of a company's shares, representing the additional capital contributed by shareholders. Sarepta Therapeutics' Additional Paid In Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sarepta Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Additional Paid In Capital | 10 Years Trend |
|
Additional Paid In Capital |
| Timeline |
Sarepta Additional Paid In Capital Regression Statistics
| Arithmetic Mean | 154,133,133 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 249.90 | |
| Mean Deviation | 209,571,396 | |
| Median | 0.00 | |
| Standard Deviation | 385,171,279 | |
| Sample Variance | 148356.9T | |
| Range | 1.5B | |
| R-Value | (0.18) | |
| Mean Square Error | 154844.2T | |
| R-Squared | 0.03 | |
| Significance | 0.53 | |
| Slope | (15,121,221) | |
| Total Sum of Squares | 2076996.8T |
Sarepta Additional Paid In Capital History
About Sarepta Therapeutics Financial Statements
Sarepta Therapeutics shareholders use historical fundamental indicators, such as Additional Paid In Capital, to determine how well the company is positioned to perform in the future. Although Sarepta Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Sarepta Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Sarepta Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Sarepta Stock Analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.